A Case of Inoperable Malignant Insulinoma with Resistant Hypoglycemia Who Experienced the Most Significant Clinical Improvement with Everolimus

被引：6

作者：

Bozkirli, Emre ^{[1
]}

Bakiner, Okan ^{[1
]}

Abali, Huseyin ^{[2
]}

Andic, Cagatay ^{[3
]}

Yapar, Ali Fuat ^{[4
]}

Kayaselcuk, Fazilet ^{[5
]}

Ertorer, Eda ^{[1
]}

机构：

[1] Baskent Univ, Sch Med, Adana Med Ctr, Div Endocrinol & Metab, Dadaloglu Mah Serin Evler 39,Sok 6 Yuregir, TR-01250 Adana, Turkey

[2] Baskent Univ, Sch Med, Adana Med Ctr, Div Med Oncol, TR-01250 Adana, Turkey

[3] Baskent Univ, Sch Med, Adana Med Ctr, Div Radiol, TR-01250 Adana, Turkey

[4] Baskent Univ, Sch Med, Adana Med Ctr, Div Nucl Med, TR-01250 Adana, Turkey

[5] Baskent Univ, Sch Med, Adana Med Ctr, Div Pathol, TR-01250 Adana, Turkey

来源：

CASE REPORTS IN ENDOCRINOLOGY | 2013年 / 2013卷

关键词：

D O I：

10.1155/2013/636175

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic insulinomas may sometimes present with recurrent life-threatening hypoglycemia episodes. Such patients usually fail to respond to various therapeutic agents which causes constant dextrose infusion requirement. Herein, we present a resistant case of inoperable malignant insulinoma who was treated with many therapeutic agents and interventions including somatostatin analogues, Yttrium-90 radioembolization, everolimus, radiotherapy, and chemoembolization. Close blood sugar monitorization during these therapies showed themost favourable response with everolimus. Everolimus treatment resulted in rapid improvement of hypoglycemia episodes, letting us discontinue dextrose infusion and discharge the patient. However, experience with everolimus in such patients is still limited, and more precise data can be obtained with the increasing use of this agent for neuroendocrine tumours.

引用

页数：6

共 22 条

[1]

Bosman F. T., 2010, WHO classification of tumours of the digestive system

[2] Management of Intractable Hypoglycemia With Yttirum-90 Radioembolization in a Patient With Malignant Insulinoma [J].